Does the assessment of biomarkers of myocardial injury (cTnI and CK-MB) predict adverse outcomes in patients with hypertrophic cardiomyopathy?
Routine assessment of cTnI and CK-MB may help guide ICD implantation for primary prevention in patients with HCM.
Comprehensive evaluations of biomarkers of myocardial injury, cTnI and CK-MB, have considerable value for predicting adverse outcomes among patients with HCM. Routine cTnI and CK-MB assessments may help to guide implantable cardioverter defibrillator implantation for primary prevention in HCM.
Zhang et al. (Fri,) studied this question.